Showing 37 to 48 of 174 results
WHO to Officially Endorse Weight-Loss Drugs for Obesity Treatment
The World Health Organization will officially endorse weight-loss drugs like Wegovy and Mounjaro for adult obesity treatment in August, addressing the over 1 billion people affected globally, with 70% in low- and middle-income countries, while acknowledging high costs and advocating for increased ac...
WHO to Officially Endorse Weight-Loss Drugs for Obesity Treatment
The World Health Organization will officially endorse weight-loss drugs like Wegovy and Mounjaro for adult obesity treatment in August, addressing the over 1 billion people affected globally, with 70% in low- and middle-income countries, while acknowledging high costs and advocating for increased ac...
Progress
32% Bias Score
UK to Extend Sugar Tax to Milkshakes
The UK government plans to extend its sugar tax to milkshakes and similar drinks by July 21, aiming to reduce sugar consumption, despite concerns about the impact on consumers and the success of the initial tax.
UK to Extend Sugar Tax to Milkshakes
The UK government plans to extend its sugar tax to milkshakes and similar drinks by July 21, aiming to reduce sugar consumption, despite concerns about the impact on consumers and the success of the initial tax.
Progress
44% Bias Score
Moderate Drinking and Obesity Double Liver Disease Risk
New research shows that even moderate alcohol consumption combined with being overweight doubles the risk of liver disease, highlighting a significant public health concern given the four-fold rise in deaths from this condition over the past two decades and the increasing number of diagnoses in thos...
Moderate Drinking and Obesity Double Liver Disease Risk
New research shows that even moderate alcohol consumption combined with being overweight doubles the risk of liver disease, highlighting a significant public health concern given the four-fold rise in deaths from this condition over the past two decades and the increasing number of diagnoses in thos...
Progress
52% Bias Score
Eli Lilly's Weight-Loss Pill Poised for Market Disruption
Eli Lilly's new weight-loss pill, showing 8% weight loss in trials, offers a more accessible treatment option compared to injectables, potentially reaching a larger patient base and generating \$100 billion in sales by 2030.
Eli Lilly's Weight-Loss Pill Poised for Market Disruption
Eli Lilly's new weight-loss pill, showing 8% weight loss in trials, offers a more accessible treatment option compared to injectables, potentially reaching a larger patient base and generating \$100 billion in sales by 2030.
Progress
64% Bias Score
High Rates of Hypertension and Obesity Among Older Adults in Mecklenburg-Vorpommern
In Mecklenburg-Vorpommern, Germany, hypertension is the most common age-related illness, affecting one in three 60-69 year-olds, rising to four in five by age 70-79 and nine in ten by 80-89. The state also has the highest obesity rate in Germany for the 60-79 age group (10.7% and 24.7% respectively)...
High Rates of Hypertension and Obesity Among Older Adults in Mecklenburg-Vorpommern
In Mecklenburg-Vorpommern, Germany, hypertension is the most common age-related illness, affecting one in three 60-69 year-olds, rising to four in five by age 70-79 and nine in ten by 80-89. The state also has the highest obesity rate in Germany for the 60-79 age group (10.7% and 24.7% respectively)...
Progress
40% Bias Score
India's Soaring Obesity Crisis: Abdominal Fat Poses Major Health Threat
India faces a rapidly escalating obesity crisis, with 180 million adults currently overweight or obeseâa number projected to reach 450 million by 2050. Abdominal obesity, linked to insulin resistance and chronic diseases, is particularly prevalent, affecting nearly 40% of women and 12% of men. New c...
India's Soaring Obesity Crisis: Abdominal Fat Poses Major Health Threat
India faces a rapidly escalating obesity crisis, with 180 million adults currently overweight or obeseâa number projected to reach 450 million by 2050. Abdominal obesity, linked to insulin resistance and chronic diseases, is particularly prevalent, affecting nearly 40% of women and 12% of men. New c...
Progress
40% Bias Score
Wegovy Ingredient Shows Promise in Treating Fatty Liver Disease
Research published in the New England Journal of Medicine shows that semaglutide, the active ingredient in Wegovy, significantly reduced liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver disease affecting an estimated 1.5% to 6.5%...
Wegovy Ingredient Shows Promise in Treating Fatty Liver Disease
Research published in the New England Journal of Medicine shows that semaglutide, the active ingredient in Wegovy, significantly reduced liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver disease affecting an estimated 1.5% to 6.5%...
Progress
48% Bias Score
UK to Extend Sugar Tax to Milkshakes
The UK government will extend its sugar tax to milkshakes and other milk-based drinks, lowering the sugar threshold to 4g per 100ml, impacting 203 products (93% of sales) to curb obesity, despite prior exemptions due to calcium concerns, and generating additional revenue.
UK to Extend Sugar Tax to Milkshakes
The UK government will extend its sugar tax to milkshakes and other milk-based drinks, lowering the sugar threshold to 4g per 100ml, impacting 203 products (93% of sales) to curb obesity, despite prior exemptions due to calcium concerns, and generating additional revenue.
Progress
40% Bias Score
Rising Cancer Deaths in the U.S. Despite Overall Decline
A new report reveals that while overall cancer deaths are declining in the U.S., deaths from several cancersâincluding melanoma, oral cancers, and those affecting bones, joints, pancreas, uterus, and liverâare increasing due to factors such as obesity, delayed diagnosis, and an aging population.
Rising Cancer Deaths in the U.S. Despite Overall Decline
A new report reveals that while overall cancer deaths are declining in the U.S., deaths from several cancersâincluding melanoma, oral cancers, and those affecting bones, joints, pancreas, uterus, and liverâare increasing due to factors such as obesity, delayed diagnosis, and an aging population.
Progress
20% Bias Score
Australian MP Advocates for Men's Health, Discloses Weight-Loss Medication Use
Australian Member of Parliament Dan Repacholi publicly discussed his use of Mounjaro, a weight-loss drug, highlighting a need for open conversation about men's health and advocating for its inclusion in the Pharmaceutical Benefits Scheme to lower costs.
Australian MP Advocates for Men's Health, Discloses Weight-Loss Medication Use
Australian Member of Parliament Dan Repacholi publicly discussed his use of Mounjaro, a weight-loss drug, highlighting a need for open conversation about men's health and advocating for its inclusion in the Pharmaceutical Benefits Scheme to lower costs.
Progress
44% Bias Score
Metabolic Syndrome Significantly Increases Breast Cancer Recurrence and Mortality Risk
A study of over 42,000 breast cancer patients revealed that metabolic syndrome increases breast cancer recurrence risk by 69% and mortality risk by 83% in survivors, highlighting the need for metabolic screening and lifestyle interventions.
Metabolic Syndrome Significantly Increases Breast Cancer Recurrence and Mortality Risk
A study of over 42,000 breast cancer patients revealed that metabolic syndrome increases breast cancer recurrence risk by 69% and mortality risk by 83% in survivors, highlighting the need for metabolic screening and lifestyle interventions.
Progress
24% Bias Score
Sirona Weight-Loss Pill Shows Promising Results in NHS Trial
A new weight-loss pill, Sirona, currently in NHS trials, shows obese patients losing an average of 3.6kg (7.9 lbs), or roughly 10%, of their body weight in 12 weeks with no reported side effects, unlike other treatments like Ozempic and Xenical.
Sirona Weight-Loss Pill Shows Promising Results in NHS Trial
A new weight-loss pill, Sirona, currently in NHS trials, shows obese patients losing an average of 3.6kg (7.9 lbs), or roughly 10%, of their body weight in 12 weeks with no reported side effects, unlike other treatments like Ozempic and Xenical.
Progress
52% Bias Score
Showing 37 to 48 of 174 results